SAB BIOTHERAPEUTICS, INC. Retained Earnings
SAB BIOTHERAPEUTICS, INC. (SABS) had Retained Earnings of -$152.25 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$152.25M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$129.76M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$110.89M; Retained Earnings (Accumulated Deficit) as first filed -$110.90M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$94.03M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$152.25M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$129.76M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | -$110.89M 10-Q · filed 2026-08-06 | -$110.90M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$94.03M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$139.48M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$129.37M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | -$124.17M 10-K · filed 2026-03-09 | |
| 2024-09-30 | -$112.77M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | -$102.42M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$95.09M 10-Q · filed 2024-05-20 | |
| 2023-12-31 | -$90.06M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$67.21M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$62.10M 10-Q · filed 2023-08-21 | |
| 2023-03-31 | -$55.22M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$47.87M 10-K · filed 2024-03-29 | |
| 2022-09-30 | -$40.00M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$32.92M 10-K · filed 2023-04-14 | |
| 2022-03-31 | -$28.14M 10-K · filed 2023-04-14 | |
| 2021-12-31 | -$29.13M 10-K/A · filed 2023-04-28 | |
| 2021-09-30 | -$9.29M 10-Q · filed 2021-11-22 | |
| 2021-06-30 | -$8.96M 10-Q · filed 2021-11-22 | $762.06K 10-Q · filed 2021-08-09 |
| 2021-03-31 | -$6.76M 10-Q · filed 2021-11-22 | $2.96M 10-Q · filed 2021-05-21 |
| 2021-01-14 | -$10.02M 10-Q · filed 2021-11-22 | -$359.98K 10-Q · filed 2021-05-21 |
| 2020-12-31 | -$11.98M 10-K/A · filed 2023-04-28 | -$9.00K 10-K · filed 2021-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |